Coya Therapeutics, Inc. (NASDAQ:COYA – Get Free Report) saw a significant growth in short interest in the month of September. As of September 15th, there was short interest totalling 173,600 shares, a growth of 7.3% from the August 31st total of 161,800 shares. Based on an average daily trading volume, of 44,800 shares, the short-interest ratio is presently 3.9 days. Currently, 1.2% of the company’s stock are sold short.
Coya Therapeutics Trading Up 7.6 %
COYA stock opened at $6.76 on Monday. Coya Therapeutics has a 1-year low of $3.21 and a 1-year high of $10.69. The business’s 50 day simple moving average is $6.14 and its 200 day simple moving average is $7.37. The firm has a market capitalization of $98.82 million, a PE ratio of -7.95 and a beta of 0.58.
Coya Therapeutics (NASDAQ:COYA – Get Free Report) last announced its earnings results on Monday, August 12th. The company reported ($0.19) EPS for the quarter. The company had revenue of $3.43 million for the quarter. As a group, sell-side analysts predict that Coya Therapeutics will post -1.27 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Report on COYA
Institutional Trading of Coya Therapeutics
Several institutional investors have recently added to or reduced their stakes in COYA. Gilbert & Cook Inc. bought a new position in shares of Coya Therapeutics during the second quarter worth approximately $61,000. Renaissance Technologies LLC acquired a new position in Coya Therapeutics in the 2nd quarter valued at $101,000. Vanguard Group Inc. lifted its position in shares of Coya Therapeutics by 772.3% during the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after acquiring an additional 750,338 shares during the period. Finally, Greenlight Capital Inc. grew its holdings in shares of Coya Therapeutics by 172.2% during the 4th quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company’s stock worth $9,441,000 after purchasing an additional 805,959 shares in the last quarter. 39.75% of the stock is currently owned by institutional investors.
Coya Therapeutics Company Profile
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Recommended Stories
- Five stocks we like better than Coya Therapeutics
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Salesforce Stock Gets a Wall Street Boost, Cloud Businesses Back?
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- 3 Multi-Bagger Stocks to Buy Now for Explosive Growth
- Investing in Construction Stocks
- Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.